Our Team Archive - Page 6 of 16

DIPANJAN CHOWDHURY, PhD & KEVIN ELIAS, MD

Project Title: “Circulating microRNA signatures among BRCA1/2 mutation carriers”

Dr. Chowdhury is a Professor of Medicine at Harvard Medical School and Chief of the Division of Radiation and Genome Stability in the Department of Radiation Oncology at the Dana-Farber Cancer Institute. Dr. Elias is an Assistant Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and a Gynecologic Oncologist and Director of the Gynecologic Oncology Laboratory at Brigham And Women’s Hospital.

Anna Gibson

Anna joined Tina’s Wish from the Cape Ann Museum’s development team (Gloucester, Massachusetts). She graduated from Vassar College with a B.A. in Science, Technology, and Society. While at Vassar she was a research associate in the Grants Office. Anna is passionate about not-for-profit work and is excited to be focusing her efforts on women’s health.

Caroline Wilson

Caroline joined Tina’s Wish in 2015 with event planning experience from the wedding and real estate industries. She started her career in consumer public relations at Golin after receiving her BS in public relations from West Virginia University. Her role at Tina’s Wish allows her to combine her two biggest passions – storytelling and bringing people together to inspire them to think, feel and take action. Caroline has planned and executed more than 50 successful fundraising events ranging from intimate receptions to a 900-person gala. She feels privileged to have the opportunity to empower women about their health and to work with brilliant researchers who are making life-changing discoveries in order to give women a fighting chance against ovarian cancer.

BEVERLY M. WOLFER

Beverly Wolfer’s professional career spans the corporate and not-for-profit sectors. Beverly worked in banking at Riggs National Bank and management consulting with Booz Allen & Hamilton. She sits on the Board of The Jewish Welfare Board, JCCA and is the President of a family foundation dedicated to supporting our Troops. Beverly received her B.B.A. from The George Washington University and her M.B.A. from The Darden School, University of Virginia.

JOYCE LIU, MD, MPH

Joyce Liu, MD, MPH, joined the staff of Dana-Farber and Brigham and Women’s Hospital in 2008, where she is a medical oncologist and clinical investigator in the Gynecologic Oncology Program. She received her MD from Harvard Medical School and completed her residency in Internal Medicine at Brigham and Women’s Hospital, and her fellowship in Hematology Oncology at the Dana-Farber Cancer Institute. Dr. Liu’s research focuses on identifying and validating potential therapeutic targets in advanced platinum-resistant ovarian cancer, in an in-vitro setting as well as in a mouse model of ovarian cancer.

Dr. Liu was awarded The Columbia Hospital Research Foundation Annual Award for Research Excellence in Breast, Obstetrical and Gynecologic Disorders.

In the 5th issue of Dana-Farber’s Inside the Institute, Dr. Liu discusses the importance of federal funding after her successful clinical trial, which was funded by the National Cancer Institute, proved that a novel two-drug combination nearly doubled progression-free survival for many women with ovarian cancer.

CHIP LANDEN, MD

Charles “Chip” Landen, MD is a gynecologic oncologist and an Associate Professor in the Gynecologic Oncology Division at the University of Virginia and the Associate Leader of the Women’s Oncology Program at the UVA Cancer Center.

Dr. Landen received his MD from the University of North Carolina School of Medicine. He completed his residency at the Medical University of South Carolina and his fellowship in gynecologic oncology at the University of Texas MD Anderson Cancer Center.

As a Tina’s Wish 2017/18 funded researcher, Dr. Landen has shown that DNA from ovarian cancer cells within the peritoneal cavity (the area that contains the abdominal organs) can be detected in the discharge collected on a tampon specimen after being placed overnight in patients with advanced ovarian cancer. Dr. Landen’s lab is performing experiments to see if this noninvasive method can be used for detection of early-stage, or even premalignant, ovarian cancer.

Enter your keyword

Archives